180 related articles for article (PubMed ID: 31179493)
1. Functional muscle recovery following dystrophin and myostatin exon splice modulation in aged mdx mice.
Lu-Nguyen N; Ferry A; Schnell FJ; Hanson GJ; Popplewell L; Dickson G; Malerba A
Hum Mol Genet; 2019 Sep; 28(18):3091-3100. PubMed ID: 31179493
[TBL] [Abstract][Full Text] [Related]
2. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy.
Kemaladewi DU; Hoogaars WM; van Heiningen SH; Terlouw S; de Gorter DJ; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; ten Dijke P; 't Hoen PA
BMC Med Genomics; 2011 Apr; 4():36. PubMed ID: 21507246
[TBL] [Abstract][Full Text] [Related]
3. Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation.
Lu-Nguyen N; Dickson G; Malerba A
Methods Mol Biol; 2018; 1828():343-354. PubMed ID: 30171552
[TBL] [Abstract][Full Text] [Related]
4. Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice.
Lu-Nguyen NB; Jarmin SA; Saleh AF; Popplewell L; Gait MJ; Dickson G
Mol Ther; 2015 Aug; 23(8):1341-1348. PubMed ID: 25959011
[TBL] [Abstract][Full Text] [Related]
5. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
Hiller M; Spitali P; Datson N; Aartsma-Rus A
Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546
[TBL] [Abstract][Full Text] [Related]
6. Use of Small Animal Models for Duchenne and Parameters to Assess Efficiency upon Antisense Treatment.
Lu-Nguyen N; Malerba A; Popplewell L
Methods Mol Biol; 2022; 2434():301-313. PubMed ID: 35213026
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Evaluation of Dystrophin Exon Skipping in mdx Mice.
Wu B; Wang M; Shah S; Lu QL
Methods Mol Biol; 2018; 1828():231-247. PubMed ID: 30171545
[TBL] [Abstract][Full Text] [Related]
8. A dystrophic Duchenne mouse model for testing human antisense oligonucleotides.
Veltrop M; van Vliet L; Hulsker M; Claassens J; Brouwers C; Breukel C; van der Kaa J; Linssen MM; den Dunnen JT; Verbeek S; Aartsma-Rus A; van Putten M
PLoS One; 2018; 13(2):e0193289. PubMed ID: 29466448
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
10. Systemic Antisense Therapeutics for Dystrophin and Myostatin Exon Splice Modulation Improve Muscle Pathology of Adult mdx Mice.
Lu-Nguyen N; Malerba A; Popplewell L; Schnell F; Hanson G; Dickson G
Mol Ther Nucleic Acids; 2017 Mar; 6():15-28. PubMed ID: 28325281
[TBL] [Abstract][Full Text] [Related]
11. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
Takeshima Y; Yagi M; Wada H; Matsuo M
Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
14. Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model.
Yavas A; Weij R; van Putten M; Kourkouta E; Beekman C; Puoliväli J; Bragge T; Ahtoniemi T; Knijnenburg J; Hoogenboom ME; Ariyurek Y; Aartsma-Rus A; van Deutekom J; Datson N
PLoS One; 2020; 15(12):e0244215. PubMed ID: 33362201
[TBL] [Abstract][Full Text] [Related]
15. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.
Mann CJ; Honeyman K; Cheng AJ; Ly T; Lloyd F; Fletcher S; Morgan JE; Partridge TA; Wilton SD
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):42-7. PubMed ID: 11120883
[TBL] [Abstract][Full Text] [Related]
16. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
17. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC
Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744
[TBL] [Abstract][Full Text] [Related]
18. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
van Deutekom JC; Bremmer-Bout M; Janson AA; Ginjaar IB; Baas F; den Dunnen JT; van Ommen GJ
Hum Mol Genet; 2001 Jul; 10(15):1547-54. PubMed ID: 11468272
[TBL] [Abstract][Full Text] [Related]
19. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.
Aoki Y; Nakamura A; Yokota T; Saito T; Okazawa H; Nagata T; Takeda S
Mol Ther; 2010 Nov; 18(11):1995-2005. PubMed ID: 20823833
[TBL] [Abstract][Full Text] [Related]
20. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
Relizani K; Goyenvalle A
Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]